UK diagnostics specialist joins FTSE 100 group

Alpha Laboratories Ltd has announced its acquisition by Diploma PLC, a FTSE 100-listed group known for delivering value-added technical products and services across Life Sciences, Seals, and Controls. The move marks a significant milestone for Alpha as it continues to expand its reach and impact in the diagnostics field.

Diploma’s decentralised, customer-focused model makes it a strong strategic fit for Alpha, one of the UK and Ireland’s fastest-growing diagnostics companies. With leading positions in bowel cancer and inflammatory bowel disease screening, Alpha’s regional expertise and innovative product range will now benefit from the backing of a major public company.

Rob Vint, Managing Director at Alpha Laboratories, commented:

“Our shared values made this an easy decision. Like Diploma, we are committed to sustainability, strong ESG practices, and clinical excellence. This partnership gives us the best of both worlds - the independence to remain agile and customer-focused, with the added strength of a group that upholds the highest standards of commercial and regulatory practice.”

Importantly, Alpha Laboratories will continue to operate as it always has: under the same name, from the same location, with the same trusted team, suppliers, and product range. Customers can expect continuity - with added benefits.

The acquisition paves the way for Alpha to accelerate innovation, strengthen its market position, and continue supporting laboratories across the UK and Ireland with trusted diagnostics solutions.

“This is a new chapter for us — one that brings new resources and opportunities, while staying true to who we are,” Vint added.

More information online